EP1171078A4 - Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein ai, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol - Google Patents

Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein ai, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol

Info

Publication number: EP1171078A4
Authority: EP; European Patent Office
Prior art keywords: cholesterol; density lipoprotein; low density; vldl; apolipoprotein
Prior art date: 1999-03-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

EP00918362A

Other languages

German (de)

French (fr)

Other versions

EP1171078A2 (en

Inventor

Michael Jaye

Kevin J Lynch

Dilip V Amin

Kim-Anh Thi Doan

Dawn Marchadier

Cyrille Maugeais

Daniel J Rader

John A Krawiec

Victoria J South

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Aventis Pharmaceuticals Inc

University of Pennsylvania Penn

Original Assignee

Aventis Pharmaceuticals Inc

University of Pennsylvania Penn

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-26

Filing date

2000-03-24

Publication date

2002-11-06

1999-03-26 Priority claimed from US09/277,401 external-priority patent/US7008776B1/en

2000-03-24 Application filed by Aventis Pharmaceuticals Inc, University of Pennsylvania Penn filed Critical Aventis Pharmaceuticals Inc

2002-01-16 Publication of EP1171078A2 publication Critical patent/EP1171078A2/en

2002-11-06 Publication of EP1171078A4 publication Critical patent/EP1171078A4/en

Status Ceased legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Genetics & Genomics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Immunology (AREA)
General Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)
Investigating Or Analysing Biological Materials (AREA)

EP00918362A 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein ai, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol Ceased EP1171078A4 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US277401		1994-07-19
US09/277,401 US7008776B1 (en)	1996-12-06	1999-03-26	Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
PCT/US2000/007870 WO2000057837A2 (en)	1999-03-26	2000-03-24	Compositions and methods for effecting the levels of cholesterol

Publications (2)

Publication Number	Publication Date
EP1171078A2 EP1171078A2 (en)	2002-01-16
EP1171078A4 true EP1171078A4 (en)	2002-11-06

Family

ID=23060703

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP00918362A Ceased EP1171078A4 (en)	1999-03-26	2000-03-24	Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein ai, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol

Country Status (13)

Country	Link
EP (1)	EP1171078A4 (en)
JP (1)	JP2002540127A (en)
KR (2)	KR20050044812A (en)
AU (1)	AU776684B2 (en)
BR (1)	BR0009333A (en)
CA (1)	CA2363486C (en)
HK (1)	HK1043309A1 (en)
IL (2)	IL145526A0 (en)
MX (1)	MXPA01009727A (en)
NO (2)	NO331779B1 (en)
NZ (2)	NZ514350A (en)
WO (1)	WO2000057837A2 (en)
ZA (1)	ZA200107598B (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7507808B2 (en) *	2002-12-12	2009-03-24	Isis Pharmaceuticals, Inc.	Modulation of endothelial lipase expression
JP5713377B2 (en)	2005-12-28	2015-05-07	ザスクリプスリサーチインスティテュート	Natural antisense and non-coding RNA transcripts as drug targets
WO2010065787A2 (en)	2008-12-04	2010-06-10	Curna, Inc.	Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
JP6091752B2 (en)	2008-12-04	2017-03-08	クルナ・インコーポレーテッド	Treatment of erythropoietin (EPO) -related diseases by suppression of natural antisense transcripts against EPO
MX2011005912A (en)	2008-12-04	2011-06-17	Opko Curna Llc	Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf.
CN102387817B (en)	2009-02-12	2018-01-30	库尔纳公司	By suppressing to treat the related diseases of BDNF for the natural antisense transcript of neurotrophic factor derived from brain (BDNF)
EP2408919B1 (en)	2009-03-16	2017-10-18	CuRNA, Inc.	Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
JP5904935B2 (en)	2009-03-17	2016-04-20	クルナ・インコーポレーテッド	Treatment of DLK1-related diseases by suppression of natural antisense transcripts against Delta-like 1 homolog (DLK1)
WO2010129746A2 (en)	2009-05-06	2010-11-11	Curna, Inc.	Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
CN103223177B (en)	2009-05-06	2016-08-10	库尔纳公司	By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene
CA3185821A1 (en)	2009-05-08	2010-11-11	Curna, Inc.	Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
CA2762369C (en)	2009-05-18	2021-12-28	Joseph Collard	Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
JP2012527248A (en)	2009-05-22	2012-11-08	クルナ・インコーポレーテッド	Treatment of TFE3 and insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcripts against transcription factor E3 (TFE3)
US8791085B2 (en)	2009-05-28	2014-07-29	Curna, Inc.	Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
WO2010148065A2 (en)	2009-06-16	2010-12-23	Curna, Inc.	Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
JP5944311B2 (en)	2009-06-16	2016-07-05	クルナ・インコーポレーテッド	Treatment of collagen gene-related diseases by suppression of natural antisense transcripts against collagen genes
EP2446036B1 (en)	2009-06-24	2017-03-01	CuRNA, Inc.	Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
EP2446037B1 (en)	2009-06-26	2016-04-20	CuRNA, Inc.	Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
JP2013500017A (en)	2009-07-24	2013-01-07	カッパーアールエヌエー，インコーポレイテッド	Treatment of sirtuin (SIRT) related diseases by blocking natural antisense transcripts to sirtuin (SIRT)
WO2011017516A2 (en)	2009-08-05	2011-02-10	Curna, Inc.	Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
US9044493B2 (en)	2009-08-11	2015-06-02	Curna, Inc.	Treatment of Adiponectin related diseases by inhibition of natural antisense transcript to an Adiponectin
JP5943836B2 (en)	2009-08-21	2016-07-05	カッパーアールエヌエー，インコーポレイテッド	Treatment of CHIP-related diseases by inhibition of natural antisense transcripts on 'HSP70 interacting protein C-terminus' (CHIP)
EP2470657B1 (en)	2009-08-25	2019-10-23	CuRNA, Inc.	Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
ES2664591T3 (en)	2009-09-25	2018-04-20	Curna, Inc.	Treatment of phylagrin-related diseases (flg) by modulating the expression and activity of the FLG gene
US9173895B2 (en)	2009-12-16	2015-11-03	Curna, Inc.	Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1
ES2661387T3 (en)	2009-12-23	2018-03-28	Curna, Inc.	Treatment of diseases related to hepatocyte growth factor (hgf) by inhibition of the natural antisense transcript to hgf
EP2515947B1 (en)	2009-12-23	2021-10-06	CuRNA, Inc.	Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
WO2011090740A2 (en)	2009-12-29	2011-07-28	Opko Curna, Llc	Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
WO2011090741A2 (en)	2009-12-29	2011-07-28	Opko Curna, Llc	TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
KR101853511B1 (en)	2009-12-31	2018-06-20	큐알엔에이, 인크.	Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
ES2664605T3 (en)	2010-01-04	2018-04-20	Curna, Inc.	Treatment of diseases related to interferon regulatory factor 8 (irf8) by inhibition of the natural antisense transcript to the irf8 gene
US8912157B2 (en)	2010-01-06	2014-12-16	Curna, Inc.	Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
US9200277B2 (en)	2010-01-11	2015-12-01	Curna, Inc.	Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
JP5981850B2 (en)	2010-01-25	2016-08-31	カッパーアールエヌエー，インコーポレイテッド	Treatment of RNase H1-related diseases by inhibition of natural antisense transcripts against RNase H1
CN102844435B (en)	2010-02-22	2017-05-10	库尔纳公司	Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
EP2553098B1 (en)	2010-04-02	2017-10-11	CuRNA, Inc.	Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
CN102858979B (en)	2010-04-09	2018-01-26	库尔纳公司	FGF21 relevant diseases are treated by suppressing the natural antisense transcript of FGF2 1 (FGF21)
KR101915115B1 (en)	2010-05-03	2018-11-05	큐알엔에이, 인크.	Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
TWI586356B (en)	2010-05-14	2017-06-11	可娜公司	Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
DK2576784T3 (en)	2010-05-26	2018-02-26	Curna Inc	TREATMENT OF METHIONIN SULPHOXIDE REDUCTASE A (MSRA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO MSRA
CN107412251A (en)	2010-05-26	2017-12-01	库尔纳公司	ATOH1 relevant diseases are treated by suppressing the natural antisense transcript of atonal homolog 1 (ATOH1)
EP2585596B1 (en)	2010-06-23	2020-12-30	CuRNA, Inc.	Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
JP5998131B2 (en)	2010-07-14	2016-09-28	カッパーアールエヌエー，インコーポレイテッド	DISCSLARGEHOMOLOG (DLG) Treatment of DLG-related diseases by inhibition of natural antisense transcripts on DLG1
US8993533B2 (en)	2010-10-06	2015-03-31	Curna, Inc.	Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
US9222088B2 (en)	2010-10-22	2015-12-29	Curna, Inc.	Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
WO2012068340A2 (en)	2010-11-18	2012-05-24	Opko Curna Llc	Antagonat compositions and methods of use
KR102010598B1 (en)	2010-11-23	2019-08-13	큐알엔에이, 인크.	Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
CN103620036B (en)	2011-06-09	2016-12-21	库尔纳公司	FXN relevant disease is treated by the natural antisense transcript of suppression Frataxin (FXN)
US10583128B2 (en)	2011-09-06	2020-03-10	Curna, Inc.	Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (SCNxA) with small molecules
EP2825648B1 (en)	2012-03-15	2018-09-05	CuRNA, Inc.	Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
CN102628060A (en) *	2012-03-22	2012-08-08	北京济福霖生物技术有限公司	Production method of low-fat milk
WO2014069651A1 (en)	2012-11-05	2014-05-08	塩野義製薬株式会社	Method for evaluating drug activity of medicine having therapeutic or preventive effect on disease to which el activity relates, and method for screening for el activity inhibitory substance
MX365484B (en)	2013-03-14	2019-06-05	Shionogi & Co	Monoclonal antibody inhibiting enzymatic activity of endothelial lipase.
TWI688575B (en)	2014-09-11	2020-03-21	日商塩野義製藥股份有限公司	Humanized monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
US20240091380A1 (en)	2021-02-01	2024-03-21	Regenxbio Inc.	Gene therapy for neuronal ceroid lipofuscinoses
WO2023008337A1 (en) *	2021-07-26	2023-02-02	ピューロテックバイオ株式会社	Anti-hepatitis b virus agent targeting host factor lipg

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998024888A2 (en) *	1996-12-06	1998-06-11	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Polypeptides encoded by a human lipase-like gene, compositions and methods
WO1999032611A1 (en) *	1997-12-19	1999-07-01	Progenitor, Inc.	A lipase expressed in endothelial cells and methods for its use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994013791A1 (en) *	1992-12-04	1994-06-23	Innovir Laboratories, Inc.	Regulatable nucleic acid therapeutic and methods of use thereof

2000
- 2000-03-24 KR KR1020057005114A patent/KR20050044812A/en active Search and Examination
- 2000-03-24 AU AU39187/00A patent/AU776684B2/en not_active Ceased
- 2000-03-24 CA CA2363486A patent/CA2363486C/en not_active Expired - Fee Related
- 2000-03-24 NZ NZ51435000A patent/NZ514350A/en not_active IP Right Cessation
- 2000-03-24 EP EP00918362A patent/EP1171078A4/en not_active Ceased
- 2000-03-24 BR BR0009333-5A patent/BR0009333A/en not_active Application Discontinuation
- 2000-03-24 JP JP2000607588A patent/JP2002540127A/en active Pending
- 2000-03-24 KR KR1020017012300A patent/KR100887164B1/en not_active IP Right Cessation
- 2000-03-24 IL IL14552600A patent/IL145526A0/en unknown
- 2000-03-24 NZ NZ531180A patent/NZ531180A/en not_active IP Right Cessation
- 2000-03-24 WO PCT/US2000/007870 patent/WO2000057837A2/en active IP Right Grant
- 2000-03-24 MX MXPA01009727A patent/MXPA01009727A/en active IP Right Grant
2001
- 2001-09-14 ZA ZA200107598A patent/ZA200107598B/en unknown
- 2001-09-20 IL IL145526A patent/IL145526A/en not_active IP Right Cessation
- 2001-09-25 NO NO20014657A patent/NO331779B1/en not_active IP Right Cessation
2002
- 2002-06-28 HK HK02104818.0A patent/HK1043309A1/en unknown
2010
- 2010-02-11 NO NO20100214A patent/NO331784B1/en not_active IP Right Cessation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998024888A2 (en) *	1996-12-06	1998-06-11	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Polypeptides encoded by a human lipase-like gene, compositions and methods
WO1999032611A1 (en) *	1997-12-19	1999-07-01	Progenitor, Inc.	A lipase expressed in endothelial cells and methods for its use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HIRATA KEN-ICHI ET AL: "Cloning of a unique lipase from endothelial cells extends the lipase gene family", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 20, 14 May 1999 (1999-05-14), pages 14170 - 14175, XP002195654, ISSN: 0021-9258 *

Also Published As

Publication number	Publication date
NO331784B1 (en)	2012-03-26
NO20100214L (en)	2001-11-21
CA2363486C (en)	2012-12-18
AU776684B2 (en)	2004-09-16
WO2000057837A3 (en)	2001-01-25
NO20014657L (en)	2001-11-21
KR20050044812A (en)	2005-05-12
WO2000057837A2 (en)	2000-10-05
KR100887164B1 (en)	2009-03-10
EP1171078A2 (en)	2002-01-16
HK1043309A1 (en)	2002-09-13
AU3918700A (en)	2000-10-16
NZ531180A (en)	2005-06-24
WO2000057837A8 (en)	2001-09-27
ZA200107598B (en)	2003-05-28
WO2000057837A9 (en)	2001-10-18
NO20014657D0 (en)	2001-09-25
IL145526A (en)	2010-11-30
IL145526A0 (en)	2002-06-30
CA2363486A1 (en)	2000-10-05
KR20020029651A (en)	2002-04-19
NZ514350A (en)	2004-12-24
BR0009333A (en)	2002-01-08
MXPA01009727A (en)	2002-07-22
NO331779B1 (en)	2012-03-26
JP2002540127A (en)	2002-11-26

Legal Events

Date	Code	Title	Description
2001-11-30	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2002-01-16	17P	Request for examination filed	Effective date: 20011017
2002-01-16	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2002-01-16	AX	Request for extension of the european patent	Free format text: AL;LT;LV;MK;RO;SI
2002-11-06	A4	Supplementary search report drawn up and despatched	Effective date: 20020925
2002-11-06	AK	Designated contracting states	Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2002-11-06	RIC1	Information provided on ipc code assigned before grant	Free format text: 7A 61K 6/00 A, 7C 12N 9/20 B
2002-11-20	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: AVENTIS PHARMACEUTICALS PRODUCTS INC. Owner name: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
2004-11-03	17Q	First examination report despatched	Effective date: 20040915
2006-02-08	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Owner name: AVENTIS PHARMACEUTICALS INC.
2006-09-13	RIN1	Information on inventor provided before grant (corrected)	Inventor name: KRAWIEC, JOHN, A. Inventor name: MARCHADIER, DAWN Inventor name: MAUGEAIS, CYRILLE Inventor name: RADER, DANIEL, J. Inventor name: JAYE, MICHAEL Inventor name: SOUTH, VICTORIA, J. Inventor name: LYNCH, KEVIN, J. Inventor name: AMIN, DILIP, V. Inventor name: DOAN, KIM-ANH, THI
2006-11-02	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: AVENTIS PHARMACEUTICALS, INC. Owner name: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
2007-01-10	RIN1	Information on inventor provided before grant (corrected)	Inventor name: LYNCH, KEVIN, J. Inventor name: RADER, DANIEL, J. Inventor name: KRAWIEC, JOHN, A. Inventor name: DOAN, KIM-ANH, THI Inventor name: MAUGEAIS, CYRILLE Inventor name: MARCHADIER, DAWN Inventor name: AMIN, DILIP, V. Inventor name: JAYE, MICHAEL Inventor name: SOUTH, VICTORIA, J.
2008-07-16	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: AVENTIS PHARMACEUTICALS INC. Owner name: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
2009-01-31	APBK	Appeal reference recorded	Free format text: ORIGINAL CODE: EPIDOSNREFNE
2009-01-31	APBN	Date of receipt of notice of appeal recorded	Free format text: ORIGINAL CODE: EPIDOSNNOA2E
2009-04-03	APBR	Date of receipt of statement of grounds of appeal recorded	Free format text: ORIGINAL CODE: EPIDOSNNOA3E
2009-04-22	APAF	Appeal reference modified	Free format text: ORIGINAL CODE: EPIDOSCREFNE
2012-03-02	APAF	Appeal reference modified	Free format text: ORIGINAL CODE: EPIDOSCREFNE
2013-09-06	REG	Reference to a national code	Ref country code: DE Ref legal event code: R003
2013-09-25	APBT	Appeal procedure closed	Free format text: ORIGINAL CODE: EPIDOSNNOA9E
2013-11-08	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED
2013-12-11	18R	Application refused	Effective date: 20130906
2014-10-17	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1043309 Country of ref document: HK

Publication	Publication Date	Title
IL145526A0 (en)	2002-06-30	Compositions and methods for effecting the levels of high density lipoprotein (hdl) chloesterol and apolipoprotein ai, very low density lipopritein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol
EE200300136A (en)	2003-08-15	Compositions and methods for lowering plasma lipoprotein (a) levels and reducing risk factors for cardiovascular disease
EP1212065A4 (en)	2004-02-11	Compositions and methods for raising hdl cholesterol levels
AU2002306930A1 (en)	2002-10-15	Plasma processor and method for operating same
AU1856997A (en)	1997-08-22	Method for raising hdl cholesterol levels
IL112593A0 (en)	1995-05-26	Methods for inhibiting bone loss and lowering serum cholesterol
EP1292603B8 (en)	2017-05-03	Methods and compositions for treating hepatitis c virus
MY121405A (en)	2006-01-28	4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines
MY130670A (en)	2007-07-31	4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
MY121838A (en)	2006-02-28	4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
AU1296099A (en)	1999-05-24	Methods and compositions for treating dermatoses
AU3531299A (en)	1999-12-06	Novel 4-phenylpiperidines for the treatment of pruritic dermatoses
AU4446400A (en)	2000-11-10	Method and apparatuses for plasma treatment
AU2003204024A1 (en)	2003-06-12	Methods for quantitating high-density lipoprotein cholesterol
AU2002221657A1 (en)	2002-05-06	Method and system for preventing the spread of computer viruses
DE69931279D1 (en)	2006-06-14	METHOD AND COMPOSITIONS FOR REDUCING THE CHOLESTEROL MIRROR IN PLASMA
AU3065999A (en)	1999-09-27	Compositions and methods for treatment of asthma
AU3074099A (en)	1999-09-27	Method and composition for lowering low density lipoprotein cholesterol
AU2001268601A1 (en)	2002-01-02	Methods and apparatus for reducing vibrations induced within fan assemblies
AU7589598A (en)	1999-01-04	Elevation of hdl cholesterol by 2-(4-chloro -1-aryl-butylidene) -hydrazinecarbothioamides
EP1089731A4 (en)	2003-06-18	Compositions and methods for treating elevated blood cholesterol
AU1683801A (en)	2001-05-30	Methods and compositions for modulating er-stress-induced cholesterol/triglyceride accumulation
AU4558799A (en)	1999-12-30	Methods and compositions for generating recombinant adeno-associated virus vectors
AU2001243614A1 (en)	2001-09-24	Phosphatidylcholine compositions and methods for lowering intestinal absorption and plasma levels of cholesterol
AU7589498A (en)	1999-01-04	Elevation of hdl cholesterol by 4-{(aminothioxomethyl)hydrazono}-4-arylbutyl carbamates